Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Trigeminal Neuralgia.Safety Issues

Next Previous
Trial Profile

Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Trigeminal Neuralgia.Safety Issues

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Trigeminal neuralgia
  • Focus Adverse reactions

    • Most Recent Events

    • 30 Jul 2020 However, the primary efficacy outcome is also stated as main efficacy endpoint (MEO) & as secondary outcome of this study in rest of the same results source (3411796).In this case, main efficacy endpoint is not the primary endpoint of the study rather it is MEO amongst all other efficacy endpoints. Hence, retained only safety as primary endpoint of this study.
    • 25 Jul 2019 Results assessing the safety and preliminary efficacy of injecting onabotulinumtoxinA (BTA) toward the sphenopalatine ganglion using the MultiGuide in patients with refractory classical trigeminal neuralgia, were published in the Headache Journal.
    • 08 Nov 2018 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top